TEVA

Teva Pharmaceutical Industries Ltd. Research & Ratings | TEVA

Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion

TD Cowen Initiates Teva Pharmaceutical Industries at Buy With $55 Price Target

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Teva stock hits 52-week high at $39.71

Teva Pharmaceutical Industries (TEVA), Why Is It Back In The Spotlight?

Teva Pharmaceutical Begins Direct Trading of Shares on NYSE

Teva stock hits 52-week high at 38.38 USD

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

Teva Pharmaceutical Industries Limited (TEVA) Latest Stock News & Headlines

Leerink Partners Initiates Coverage on Teva Pharmaceutical Industries With Outperform Rating, $45 Price Target

Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study - Slideshow (NYSE:TEVA) 2026-09-04

S&P upgrades Teva rating on deleveraging and pipeline strength

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

UBS raises Teva Pharmaceutical stock price target on celiac progress